DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1×1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.
To schedule a 1×1 meeting with the Company, please contact your Wells Fargo institutional sales representative.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
This press release was published by a CLEAR® Verified individual.
Integration Simplifies ICHRA Administration Through HR and Payroll Data SyncINDIANAPOLIS, Jan. 13, 2026 /PRNewswire/ --…
Recognition underscores Brillio's AI-driven innovation and measurable impact on health outcomes, cost, patient experience, and…
Healthcare Technology Leader Received Top Recognition for Innovative Approachto Remote Care for Chronic Disease ManagementSEATTLE,…
PITTSBURGH, Jan. 13, 2026 /PRNewswire/ -- "I wanted to create a simple and easy way…
Tenth annual awards evaluate 24 leading health insurers across 120+ digital attributes spanning desktop and…
More than 100 new and expanded LifeSphere customers, 34 global go-lives, and rapid enterprise adoption…